Quentir Medicine Monitor
Evidence-based insights for quantum medicine. Published by Quentir Systems LLC · November 13, 2026.

Chugai Pharmaceutical will test whether a quantum computer can sharpen one hard question in its chemistry labs: which reaction route makes a complex medicine cleanly, and which side reactions compete with it. The work is part of a quantum-classical hybrid project with QSimulate and Mitsui & Co., announced in Tokyo on 12 November 2026, and it targets drug-substance synthesis, the chemistry that produces the active ingredient of a medicine.
The announcement has two parts. The three companies will extend QIDO, a computational chemistry platform sold by Mitsui and QSimulate, with functions built around needs that came out of Chugai's own evaluation of the software. Separately, a research theme with Chugai as lead proposer and QSimulate as co-proposer has been selected for the JHPC-quantum Test User Program, a Japanese government-funded platform that links quantum computers with supercomputers. Mitsui joins that theme as a cooperating party. The Japanese press release on PR TIMES and a shorter English notice from QSimulate carry the details. The announcement reports no calculation results.
What Chugai, QSimulate and Mitsui announced in Tokyo on 12 November 2026
QIDO stands for Quantum-Integrated Discovery Orchestrator. Mitsui, QSimulate and the quantum computing company Quantinuum launched it in August 2025, and it incorporates Quantinuum's InQuanto quantum chemistry software. According to the QIDO product page, the classical side of the platform already identifies transition states automatically once a chemist specifies reactants and products, and computes more precise energies with post-Hartree-Fock methods on an active space of electrons chosen with the AVAS method. The quantum side is where InQuanto comes in.
The new functions listed in the release fall into three groups. The first deepens reaction-mechanism analysis and reaction-path search for the complex molecules and reactions that pharmaceutical research handles. The second extends workflows that generate and evaluate candidate structures for reactants, products, intermediates and transition states. The third improves the interface through which a chemist sets and checks calculation conditions. The companies say these functions will enter the QIDO product roadmap and be offered to other pharmaceutical and chemical companies as general product features, so requirements that came from Chugai's laboratories will shape software that other companies can buy.
The division of labor is explicit. Chugai supplies the research problems and use cases from drug-substance process development, helps define the functional requirements, and judges the scientific validity of results produced with QIDO. QSimulate builds the product functions and the calculation workflows. Mitsui handles theme definition, coordination and commercialization, and Quantinuum advises on InQuanto and on the connection to quantum hardware. Akihiko Arakawa, a data scientist in Chugai's digital strategy department, is quoted as saying that the company will evaluate whether the hybrid analysis is applicable to pharmaceutical research.
Why Chugai is aiming at drug-substance synthesis and side reactions
Most quantum chemistry stories in medicine concern discovery: how tightly a candidate molecule binds its target protein. This project sits one step later. Once a molecule is chosen, a process chemist has to find a route that makes it at scale, with acceptable yield and a predictable set of byproducts. The release notes that the chemical structures of medicines are becoming more complex, and that this raises the difficulty of developing the synthesis process for the drug substance. Its stated goal is to understand reaction mechanisms in detail, predict reaction paths and side reactions with high accuracy, and narrow down promising routes and conditions on that basis.
Side reactions matter to patients because they produce impurities. The international guideline on drug-substance development, ICH Q11 of 1 May 2012, calls impurities an important class of critical quality attributes because of their potential impact on drug safety, and says that for chemical medicines a major focus is knowledge and control of impurities, including their formation, fate and purge through the process. A calculation that tells a chemist in advance which side reaction is energetically favored would feed directly into that work. The release frames the quantum contribution in exactly those terms: a more precise evaluation of the electronic states and energy differences that separate the intended reaction from its side reactions.
Quantum pillar: computing. Technology readiness: TRL 3 of 9. Quentir places the quantum step at this level because working software for it exists in QIDO through Quantinuum's InQuanto, while its use on real reactions from Chugai's process chemistry is only now being evaluated and the announcement reports no results.
How QIDO divides the work between ROQUO, Reimei and ibm_kobe
The workflow is staged. Large-scale reaction-path analysis runs on supercomputers and graphics processors. Classical calculation then selects the reaction center, the small group of atoms and electrons where bonds actually break and form. Only that center goes to a quantum algorithm, which evaluates its electronic state and energy. The release states plainly that the quantum computer does not replace the whole calculation, and that the project will test whether this targeted use gives more precise energies for the reactions that matter.
Three machines on the JHPC-quantum platform are under consideration: Quantinuum's Reimei trapped-ion quantum computer at RIKEN in Wako, the IBM Quantum System Two installation known as ibm_kobe, and ROQUO, the GPU supercomputer that entered operation for the platform in July 2026. On 10 November 2026, RIKEN marked an expanded partnership with Quantinuum after a significant upgrade of Reimei, which RIKEN's Mitsuhisa Sato described as able to handle larger problems than the previous H1 system. If the team uses both machines, it can compare a trapped-ion and a superconducting quantum computer on the same chemistry problem.
QSimulate is known to Quentir readers from another Japanese drug company. Its QUELO software is used by Daiichi Sankyo in several drug discovery programs to predict binding affinity, a discovery-stage task. The Chugai project moves the same company's chemistry toward manufacturing route design, a different question with a different payoff.
What the JHPC-quantum Test User Program requires from Chugai and QSimulate
JHPC-quantum is run by the RIKEN Center for Computational Science under a project of NEDO, the Japanese research funding agency overseen by the Ministry of Economy, Trade and Industry, within its post-5G infrastructure program. Its principal investigator is Mitsuhisa Sato. The test user program page sets the terms. Selected teams must actually use the platform's integrated software, should complete their work within about twelve months, and can lose the selection if no memorandum of understanding is signed within six months. The review panel scores each proposal on four published criteria: its scientific and practical merit, its usefulness as a quantum and supercomputer hybrid, its technical feasibility and the appropriateness of the computing resources it requests. The program's list of expected use cases includes vaccine development and small-molecule drug discovery.
The program terms split intellectual property three ways. Algorithms and software the test user runs or develops on the platform, its input and output data, and its research results and know-how belong to the test user alone. The hybrid platform and software newly developed by the project, improvements to the platform's functions and performance that draw on users' results, and the background technology of the quantum computers and supercomputers belong to the project alone. A third category is handled jointly: a disclosable overview of the theme, usage data such as run times and queue waits, and the problems users find with the platform. The project passes jointly handled information to NEDO, including the institution's name, an overview of its algorithms or software, and progress, and it may ask a team to allow publication of its results as a reference case. Presentations of results require an application in advance under the approval procedure for NEDO project results, with the project approving them and reporting to NEDO and with an acknowledgment of NEDO; a presentation that concerns only intellectual property belonging solely to the outside participant falls outside that procedure. The release adds what Chugai's team will assess: technical feasibility, scientific validity, reproducibility and operational issues of a workflow that combines classical, GPU and quantum computing.
What hospital pharmacists and medicine buyers can take from the Chugai project
Nothing in this announcement changes a medicine on a hospital formulary. Its interest for clinical readers lies in where it places quantum computing in the pharmaceutical chain. Process chemistry determines how reliably an active ingredient can be made and which impurities a regulator will ask about, and these are the properties that later surface as supply continuity and batch quality. A quantum calculation that improves route selection would act years before a medicine reaches a ward, and its effect would show up as a better-understood impurity profile.
The useful test of this project would be a public comparison, if the partners choose to report one; the announcement makes no commitment to publish results. Chugai has said it will judge scientific validity and reproducibility, and the program runs for about a year. A publicly reported comparison would be most useful if it gave, for one or more real reactions from Chugai's development work, the energy differences computed with and without the quantum step, the hardware used, and whether the quantum estimate changed which route a chemist would choose. A report that shows only that the workflow ran would leave the central question unanswered.
Sources
Primary source: press release of Mitsui & Co. and Quantum Simulation Technologies (QSimulate), issued with Chugai Pharmaceutical in Tokyo on 12 November 2026, quoting Akihiko Arakawa (Chugai), Toru Shiozaki (QSimulate) and Simon McAdams (Quantinuum). Also drawn on: the JHPC-quantum test user program terms, RIKEN's announcement of 10 November 2026, the QIDO product page, the ICH Q11 guideline, and earlier Quentir coverage.